Novel oral anticoagulants. Part II: Direct thrombin inhibitors

Rohtesh S. Mehta

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and could soon be ready to transform the history of coagulation medicine. The first part of this article (published in last months Expert Review of Hematology) embraced a comprehensive review of oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban, YM150. This second part of the article reviews novel oral direct thrombin inhibitors, such as dabigatran and AZD0837, and a brief description of oral Factor IXa inhibitors, such as TTP889.

Original languageEnglish (US)
Pages (from-to)351-361
Number of pages11
JournalExpert Review of Hematology
Issue number3
StatePublished - Jun 2010
Externally publishedYes


  • Blood thinners
  • DVT
  • Direct thrombin inhibitors
  • Factor IXa inhibitors
  • Factor Xa inhibitors
  • Heparin alternatives
  • Hip replacement prophylaxis
  • Knee replacement prophylaxis
  • Novel anticoagulants
  • Oral anticoagulants
  • Prophylaxis DVT
  • Prophylaxis VTE
  • VTE


Dive into the research topics of 'Novel oral anticoagulants. Part II: Direct thrombin inhibitors'. Together they form a unique fingerprint.

Cite this